Globally, some of the key players, such as MeiraGTx, Applied Genetic Technologies Corp, and others, are developing potential therapies for the treatment of Cone Dystrophy. The launch of emerging therapies is expected to significantly impact the treatment scenario of Cone rod dystrophies in the upcoming years.
DelveInsight’s “Cone Rod Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cone Rod Dystrophy market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Cone Rod Dystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cone Rod Dystrophy: An Overview
Cone-rod dystrophy (CRD) is a group of related eye disorders that causes vision loss, which becomes more severe over time. CRD is characterized by primary cone involvement or, sometimes, by concomitant loss of both cones and rods, which explains the predominant symptoms of CRDs. Initial signs and symptoms that usually occur in childhood may include decreased sharpness of vision (visual acuity) and abnormal sensitivity to light (photophobia).
There are more than 30 types of cone-rod dystrophy, distinguished by their genetic cause and inheritance pattern: autosomal recessive, autosomal dominant, and X-linked. Additionally, cone-rod dystrophy can occur alone without any other signs and symptoms, or it can occur as part of a syndrome that affects multiple body parts.
Cone Rod Dystrophy Market Key Facts
-
According to the National Institutes of Health (n.d.), CRD is estimated to affect 1 in 30,000 to 40,000 individuals.
-
According to Orphanet Journal of Rare Diseases, the estimated prevalence of CRDs is 1 in 40,000 in Europe. The four most commonly mutated genes are ABCA4 (1p22.1), responsible for 30 to 60% of autosomal recessive CRDs, CRX (19q13.33), and GUCY2D (17p13.1).
-
According to the NORD, cone dystrophy affects males and females in equal numbers when it occurs sporadically or is inherited in an autosomal dominant or recessive pattern. The X-linked form of cone dystrophy only affects males fully, although some females may have mild symptoms of the disorder.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Cone Rod Dystrophy market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Cone Rod Dystrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Cone Rod Dystrophy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Cone Rod Dystrophy Epidemiology Segmentation
-
Total Prevalent Cases of Cone rod dystrophies
-
Type-specific Cases of Cone rod dystrophies
-
Diagnosed and treatable cases of Cone rod dystrophies
-
Inheritance-specific Cases of Cone rod dystrophies
Cone Rod Dystrophy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cone Rod Dystrophy market or expected to be launched during the study period. The analysis covers the Cone Rod Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cone Rod Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Cone Rod Dystrophy Market Will Evolve by 2032 @
https://www.delveinsight.com/sample-request/cone-rod-dystrophy-market
Cone Rod Dystrophy Therapeutics Analysis
With no proven treatments for Cone rod dystrophy (CRD) that halt progression or restore lost vision, the therapeutic management and interventions aimed at slowing down the degenerative process, treating the complications, and helping patients to cope with the social and psychological impact of blindness and consists of symptomatic alleviation, including refractive correction, use of tinted spectacles/contact lenses for photophobia and low vision aids.
Cone Rod Dystrophy Therapies Covered in the Report Include:
-
AAV-RPGR
-
AGTC-501
-
AAV8-RPGR
And many others
The Leading Companies in the Cone Rod Dystrophy Therapeutics Market Include:
-
MeiraGTx
-
Nightstar Therapeutics
-
Applied Genetic Technologies Corp
And many more
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
https://www.delveinsight.com/sample-request/cone-rod-dystrophy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cone Rod Dystrophy Competitive Intelligence Analysis
4. Cone Rod Dystrophy Market Overview at a Glance
5. Cone Rod Dystrophy Disease Background and Overview
6. Cone Rod Dystrophy Patient Journey
7. Cone Rod Dystrophy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Cone Rod Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Cone Rod Dystrophy Unmet Needs
10. Key Endpoints of Cone Rod Dystrophy Treatment
11. Cone Rod Dystrophy Marketed Products
12. Cone Rod Dystrophy Emerging Drugs and Latest Therapeutic Advances
13. Cone Rod Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Cone Rod Dystrophy Market Outlook (In US, EU5, and Japan)
16. Cone Rod Dystrophy Access and Reimbursement Overview
17. KOL Views on the Cone Rod Dystrophy Market
18. Cone Rod Dystrophy Market Drivers
19. Cone Rod Dystrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/cone-rod-dystrophy-market
Other Trending Healthcare Reports By DelveInsight
Cone Rod Dystrophy Pipeline Insight
“Cone Rod Dystrophy Pipeline Insights, 2022”, report by DelveInsight, outlays comprehensive insights into the present clinical development scenario and growth prospects across the Cone Rod Dystrophy market.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/